Metastatic colorectal cancer: Integrating irinotecan into combination and sequential chemotherapy

Annals of Oncology

Volumn 14, Issue SUPPL. 2, 2003, Pages

  Douillard, J Y ^a   Sobrero, A ^b   Carnaghi, C ^c   Comella, P ^d   Diaz Rubio E ^e   Santoro, A ^c   Van Cutsem, E ^f  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b UNIVERSITY OF GENOA   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ALOPECIA; ARTICLE; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HUMAN; METASTASIS; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STOMATITIS; THROMBOEMBOLISM;

EID: 0037924354     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg723     Document Type: Article

References (28)

1. Scheithauer W, Rosen H, Kornek GV et al. Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993; 306: 752-755.
2. Jonker DJ, Maroun JA, Kocha W. Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Br J Cancer 2000; 82: 1789-1794.
3. Tournigand C, Louvet C, Quinaux E et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study. Proc Am Soc Clin Oncol 2001; 20: 494 (Abstr).
4. Bleiberg H. Role of chemotherapy for advanced colorectal cancer: new opportunities. Semin Oncol 1996; 23 (Suppl 3): 42-50.
5. Cunningham D, James RD. Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer. Eur J Cancer 2001; 37: 826-834.
6. Grivicich I, Mans DR, Peters GJ, Schwartsmann G. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer. Braz J Med Biol Res 2001; 34: 1087-1103.
7. Rothenberg ML. Efficacy of oxaliplatin in the treatment of colorectal cancer. Oncology 2000; 14 (Suppl 11): 9-14.
8. Nordic Gastrointestinal Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992; 10: 904-911.
9. Ackland SP, Moore M, Jones M et al. A meta-analysis of two randomized trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Proc Am Soc Clin Oncol 2001; 20: 526 (Abstr).
10. Cunningham D, Pyrhonen S, James RD et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
11. Rougier P, Van Cutsem E, Bajetta E et al. Randomized trial of irinotecan vs fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 35: 1407-1412.
12. Douillard J-Y, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000; 355: 1041-1047.
13. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905-914.
14. Comella P, Crucitta E, De Vita F et al. Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group. Ann Oncol 2002; 13: 866-873.
15. De Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
16. Knight RD, Miller LL, Pirotta N et al. First-line irinotecan (C), fluorouracil (F), leucovorin (L) especially improves survival (OS) in metastatic colorectal cancer (MCRC) patients (pt) with favorable prognostic indicators. Proc Am Soc Clin Oncol 2000; 19: 991 (Abstr).
17. Grothey A, Deschler B, Kroening H et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs. weekly high-dose 24h 5-fu infusion/A + oxaliplatin (FUFOX) in advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 2002; 21: 512 (Abstr).
18. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-115.
19. Borner M, Schoeffski P, de Wit R et al. A randomized crossover trial comparing oral UFT (Uracil/Tegafur) + leucovorin (LV) and intravenous fluorouracil (FU) + LV for patient preference and pharmacokinetics in advanced colorectal cancer. Proc Am Soc Clin Oncol 2000; 19: 741 (Abstr).
20. Koehne CH, Cunningham D, Di CF et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-317.
21. Van Cutsem E, Rougier P, Droz JP et al. Clinical benefits of irinotecan in metastatic colorectal cancer (CRC) resistant to 5-FU. Proc Am Soc Clin Oncol 1997: 16: 950 (Abstr).
22. Van Hoff DD, Rothenberg NL, Pitot HC et al. Irinotecan (CPR-11) therapy for patients with previously treated metastatic colorectal cancer (CRC): overall results of FDA-reviewed pivotal US clinical trials. Proc Am Soc Clin Oncol 1997; 16: 803 (Abstr).
23. 2, or an individual dose optimisation, or a risk factor optimisation in patients with metastatic colorectal cancer previously treated with 5FU. Proc Am Soc Clin Oncol 2000; 19: 244a (Abstr 946).
24. Rothenberg M, Meropol N, Poplin E et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19: 3801-3807.
25. Van Cutsem E, Kohne H, Douillard JY. Toxicity of irinotecan in patients with colorectal cancer. N Engl J Med 2001; 345: 1351-1352.
26. Sargent D, Niedzwiecki D, O'Connel M, Schilsky R. Recommendations for caution with irinotecan, fluorouracil and leucovorin for colorectal cancer. N Engl J Med 2001; 345: 141-145.
27. Presented at the ODAC meeting, held in the United States on December 6, 2001.
28. Ledermann JA, Leonard P, Seymour M. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001; 345: 145-146.